JP Morgan Downgrades Amrize to Neutral, Reduces PT

JP Morgan downgraded Amrize to 'Neutral' and reduced its price target. BofA also downgraded Amrize to 'Underperform' with a $40 price target. Amrize's stock has declined 2.76% in the past year and 19.99% since January 1st.

Original reporting
Published Sep 2, 2026, 12:44 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 3, 2026, 12:21 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
MARKET
Neutral
AI market analysis
Mentioned
$AMRZ
Relevance
6/10
AlphAI data visualization · based on marketscreener.com
Decision brief

The 30-second read

Med
01

Why it matters

The downgrade suggests a neutral outlook, potentially prompting short-term sell pressure.

02

Market read

Analyst rating changes can influence investor sentiment and short-term price movement.

03

What to watch

Recent contract wins or cost reductions not mentioned could offset the rating change.

Relevance 6/10Novelty 5/10Timing: pre-market today

Background

JP Morgan issued a new analyst rating, moving Amrize to Neutral and lowering its price target.

Market effects

Potential downward pressure on peers in the same industry as Amrize.

Limited to markets where Amrize is listed; no broad regional effect.

Minimal global impact given the company's size and niche.

Counterpoint

The downgrade may be premature if recent fundamentals remain strong.

Key entities

  • Amrize

    Subject of the downgrade.

  • JP Morgan

    Issuer of the rating change.

Related articles

Low

Amrize (SWX:AMRZ) Reshuffles Building Envelope Leadership As Fair Value Stays In Focus

Amrize (SWX:AMRZ) appointed Mario Gross as President of its Building Envelope division following Jake Gosa's resignation. The company's shares trade at CHF32.07, down 15.3% over the past month and 28.5% over the last quarter. Analysts suggest a fair value of CHF46.66, citing potential earnings power and margin expansion from the ASPIRE synergy program. The P/E ratio is 17.3x, compared to an estimated fair ratio of 30.5x and a peer average of 48.6x.

High

BofA downgrades Amrize to underperform, cuts price target on slower growth outlook

Bank of America downgraded Amrize to Underperform, cutting its price target to $40 from $50 due to slower earnings growth, market risks, and valuation concerns. The brokerage lowered its 2027-28 adjusted EBITDA and EPS estimates, citing stable U.S. cement prices, Canadian demand pressure from U.S. tariffs, and vulnerable roofing margins. BofA forecasts adjusted EBITDA growth of 3% and adjusted EPS growth of 6% annually over 2026-28, excluding large acquisitions. The bank also trimmed its buildin

$AMRZMed

BofA downgrades Amrize stock on growth concerns, cuts price target to $40

BofA Securities downgraded Amrize Ltd (NYSE:AMRZ) to Underperform, cutting its price target to $40 from $50. The stock is near its 52-week low, down 20% YTD. BofA reduced 2027-28 EBITDA estimates by 3%, citing growth concerns, U.S. cement price stability, and Canada macro risks. Amrize's Q2 earnings missed estimates, though revenue beat forecasts. Other analysts also downgraded the stock due to earnings misses and management changes.

High

Why is Amrize stock sliding today?

Amrize AG (AMRZ) fell 2.9% to CHF 34.13 after JPMorgan downgraded it to Neutral, citing executive departures and missed earnings. The stock hit a 52-week low of CHF 33.64, with JPMorgan lowering its price target to $52 from $57. The broader market showed no significant movement, indicating the decline is company-specific.